- NewGen IVF Group (NIVF, Financial) files 2024 annual report showing strong cash position exceeding market cap.
- Company has improved financial status by settling outstanding debts and converting notes to equity.
- Maintains access to $100M equity line of credit with $7.1M already utilized.
NewGen IVF Group (NIVF), a leading provider of fertility services in Asia, announced the filing of its 2024 annual report on Form 20-F with the SEC on April 22, 2025. The report highlights a robust cash position, with the company holding $2.48 million in cash and a $1 million deposit with a trading platform, surpassing its current market capitalization of $1.48 million.
The company has taken significant steps to strengthen its financial standing by settling all outstanding promissory notes and converting several mandatory additional notes into equity. This move has enabled NewGen to present a healthier balance sheet amidst challenging market conditions.
NewGen also announced that it retains access to a substantial $100 million equity line of credit facility, having already drawn approximately $7.1 million. This financial flexibility positions the company to pursue strategic opportunities as it continues to provide comprehensive fertility services across its clinics in Thailand, Cambodia, and Kyrgyzstan.
